Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 1459790, 11 pages
http://dx.doi.org/10.1155/2016/1459790
Research Article

Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis

1Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
2The First Clinical Medical College, Nanjing Medical University, Nanjing 210029, China
3The First Affiliated Hospital of Soochow University, Suzhou 215006, China

Received 21 January 2016; Accepted 18 July 2016

Academic Editor: Michel Kahaleh

Copyright © 2016 Wenxia Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Angulo, “Nonalcoholic fatty liver disease,” The New England Journal of Medicine, vol. 346, no. 16, pp. 1221–1231, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. F.-S. Zhu, S. Liu, X.-M. Chen, Z.-G. Huang, and D.-W. Zhang, “Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia,” World Journal of Gastroenterology, vol. 14, no. 41, pp. 6395–6400, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. R. Pagadala and A. J. McCullough, “The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis,” Clinics in Liver Disease, vol. 16, no. 3, pp. 487–504, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Lizardi-Cervera and D. Aguilar-Zapata, “Nonalcoholic fatty liver disease and its association with cardiovascular disease,” Annals of Hepatology, vol. 8, no. 1, pp. S40–S43, 2009. View at Google Scholar · View at Scopus
  5. G. Targher, C. P. Day, and E. Bonora, “Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease,” The New England Journal of Medicine, vol. 363, no. 14, pp. 1341–1350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. L. S. Bhatia, N. P. Curzen, P. C. Calder, and C. D. Byrne, “Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?” European Heart Journal, vol. 33, no. 10, pp. 1190–1200, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Targher and C. D. Byrne, “Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 2, pp. 483–495, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. C. K. Argo, P. G. Northup, A. M. S. Al-Osaimi, and S. H. Caldwell, “Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis,” Journal of Hepatology, vol. 51, no. 2, pp. 371–379, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology,” Gastroenterology, vol. 142, no. 7, pp. 1592–1609, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. A. P. Levene and R. D. Goldin, “The epidemiology, pathogenesis and histopathology of fatty liver disease,” Histopathology, vol. 61, no. 2, pp. 141–152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO), “EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease,” Journal of Hepatology, vol. 64, no. 6, pp. 1388–1402, 2016. View at Google Scholar
  12. M. Tiikkainen, A.-M. Häkkinen, E. Korsheninnikova, T. Nyman, S. Mäkimattila, and H. Yki-Järvinen, “Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes,” Diabetes, vol. 53, no. 8, pp. 2169–2176, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. A. J. Sanyal, N. Chalasani, K. V. Kowdley et al., “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 362, no. 18, pp. 1675–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. H. Hoofnagle, M. L. Van Natta, D. E. Kleiner et al., “Vitamin e and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis,” Alimentary Pharmacology and Therapeutics, vol. 38, no. 2, pp. 134–143, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. M. Younossi, M. J. Reyes, A. Mishra, R. Mehta, and L. Henry, “Systematic review with meta-analysis: non-alcoholic steatohepatitis—a case for personalised treatment based on pathogenic targets,” Alimentary Pharmacology and Therapeutics, vol. 39, no. 1, pp. 3–14, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Mazzella, L. M. Ricciardi, A. Mazzotti, and G. Marchesini, “The role of medications for the management of patients with NAFLD,” Clinics in Liver Disease, vol. 18, no. 1, pp. 73–89, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Ratziu, Z. Goodman, and A. Sanyal, “Current efforts and trends in the treatment of NASH,” Journal of Hepatology, vol. 62, no. 1, pp. S65–S75, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Araya, R. Rodrigo, L. A. Videla et al., “Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease,” Clinical Science, vol. 106, no. 6, pp. 635–643, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Promrat, D. E. Kleiner, H. M. Niemeier et al., “Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis,” Hepatology, vol. 51, no. 1, pp. 121–129, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Lazo and J. M. Clark, “The epidemiology of nonalcoholic fatty liver disease: a global perspective,” Seminars in Liver Disease, vol. 28, no. 4, pp. 339–350, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. P. Simopoulos, “Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet,” World Review of Nutrition and Dietetics, vol. 102, pp. 10–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. I. P. J. Alwayn, K. Gura, V. Nosé et al., “Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease,” Pediatric Research, vol. 57, no. 3, pp. 445–452, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M.-T. Wu, H.-N. Chou, and C.-J. Huang, “Dietary fucoxanthin increases metabolic rate and upregulated mRNA expressions of the PGC-1alpha network, mitochondrial biogenesis and fusion genes in white adipose tissues of mice,” Marine Drugs, vol. 12, no. 2, pp. 964–982, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Kromhout, S. Yasuda, J. M. Geleijnse, and H. Shimokawa, “Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?” European Heart Journal, vol. 33, no. 4, pp. 436–443, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Zhang, J. Yang, R. Zhu et al., “Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis,” Drug Design, Development and Therapy, vol. 9, pp. 567–574, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Zhang, S. Li, L. He et al., “Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis,” Drug Design, Development and Therapy, vol. 9, pp. 2757–2766, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. C. K. Argo, J. T. Patrie, C. Lackner et al., “Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial,” Journal of Hepatology, vol. 62, no. 1, pp. 190–197, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Scorletti, L. Bhatia, K. G. Mccormick et al., “Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME study,” Hepatology, vol. 60, no. 4, pp. 1211–1221, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. A. J. Sanyal, M. F. Abdelmalek, A. Suzuki, O. W. Cummings, and M. Chojkier, “No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial,” Gastroenterology, vol. 147, no. 2, pp. 377–384.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Sofi, I. Giangrandi, F. Cesari et al., “Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study,” International Journal of Food Sciences and Nutrition, vol. 61, no. 8, pp. 792–802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Dasarathy, J. Dasarathy, A. Khiyami et al., “Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis,” Journal of Clinical Gastroenterology, vol. 49, no. 2, pp. 137–144, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Spadaro, O. Magliocco, D. Spampinato et al., “Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease,” Digestive and Liver Disease, vol. 40, no. 3, pp. 194–199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Capanni, F. Calella, M. R. Biagini et al., “Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 8, pp. 1143–1151, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. G. L. Vega, M. Chandalia, L. S. Szczepaniak, and S. M. Grundy, “Effects of N-3 fatty acids on hepatic triglyceride content in humans,” Journal of Investigative Medicine, vol. 56, no. 5, pp. 780–785, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Chen, Q. Guo, W.-J. Zhu, Q. Xie, H. Wang, and W. Cai, “Therapeutic efficacy of ω-3 polyunsaturated fatty acid capsule in treatment of patients with non-alcoholic fatty liver disease,” World Chinese Journal of Digestology, vol. 16, no. 18, pp. 2002–2006, 2008. View at Google Scholar · View at Scopus
  36. I. P. J. Alwayn, C. Andersson, B. Zauscher, K. Gura, V. Nosé, and M. Puder, “Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor,” Transplantation, vol. 79, no. 5, pp. 606–608, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. H. M. Parker, N. A. Johnson, C. A. Burdon, J. S. Cohn, H. T. O'Connor, and J. George, “Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis,” Journal of Hepatology, vol. 56, no. 4, pp. 944–951, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Tanaka, K. Sano, A. Horiuchi, E. Tanaka, K. Kiyosawa, and T. Aoyama, “Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis,” Journal of Clinical Gastroenterology, vol. 42, no. 4, pp. 413–418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Zúñiga, M. Cancino, F. Medina et al., “N-3 PUFA supplementation triggers PPAR-α activation and PPAR-α/NF-κB interaction: anti-inflammatory implications in liver ischemia-reperfusion injury,” PLoS ONE, vol. 6, no. 12, Article ID e28502, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. B. Lombardo and A. G. Chicco, “Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review,” Journal of Nutritional Biochemistry, vol. 17, no. 1, pp. 1–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Ishii, Y. Horie, S. Ohshima et al., “Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice,” Journal of Hepatology, vol. 50, no. 3, pp. 562–571, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Cortez-Pinto, L. Jesus, H. Barros, C. Lopes, M. C. Moura, and M. E. Camilo, “How different is the dietary pattern in non-alcoholic steatohepatitis patients?” Clinical Nutrition, vol. 25, no. 5, pp. 816–823, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Toshimitsu, B. Matsuura, I. Ohkubo et al., “Dietary habits and nutrient intake in non-alcoholic steatohepatitis,” Nutrition, vol. 23, no. 1, pp. 46–52, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. A. M. Zivkovic, J. B. German, and A. J. Sanyal, “Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease,” American Journal of Clinical Nutrition, vol. 86, no. 2, pp. 285–300, 2007. View at Google Scholar · View at Scopus
  45. P. Cheng, K. Chen, Y. Xia et al., “Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis,” Drug Design, Development and Therapy, vol. 8, pp. 1277–1286, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. W. Dai, F. Wang, L. He et al., “Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: partial mediation by the transcription factor NFAT1,” Molecular Carcinogenesis, vol. 54, no. 4, pp. 301–311, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. W. Dai, F. Wang, J. Lu et al., “By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice,” Oncotarget, vol. 6, no. 15, pp. 13703–13717, 2015. View at Publisher · View at Google Scholar · View at Scopus